Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

NCT04863430 | Withdrawn Phase 2

• 1 other identifier: GC01
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Gastric cancer is a highly heterogeneous tumor. The most commonly used clinical classifications of gastric cancer are Lauren classification (intestinal, diffuse, mixed) and World Health Organization(WHO) classification (papillary adenocarcinoma, tubular adenocarcinoma, mucinous glands cancer and low-adhesion cancer). Hepatoid adenocarcinoma of the stomach (HAS) is a special and rare type of gastric cancer. Compared with ordinary gastric cancer, HAS has unique clinicopathological characteristics, prone to liver metastasis and lymph node metastasis, has a highly aggressive and malignant biological behavior, a worse prognosis than alpha fetoprotein(AFP) normal gastric cancer, and is easily confused with hepatocellular carcinoma(HCC). There is the possibility of misdiagnosis and mistreatment, so it has gradually attracted people's attention. Most of the domestic and foreign literature on HAS in the past 30 years are retrospective cases or small sample reports, and there are few prospective studies. There is no standard treatment plan for HAS. The main treatment is based on gastric adenocarcinoma. The clinical treatment principle is a comprehensive treatment plan with surgical resection as the mainstay, supplemented by systemic chemotherapy and local interventional therapy. This type of gastric cancer has a relatively high degree of malignancy, rapid progress of the disease, and easy recurrence after surgery. There is no standard treatment plan in China and other foreign countries. The aim of this study was to evaluate the efficacy and safety of apatinib with oxaliplatin and S-1 treatment advanced hepatoid adenocarcinoma of the stomach.

Conditions

Gastric Cancer

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate（ORR）

  The percentage of patients having a complete response(CR) or a partial response(PR) to protocol treatment. Objective response will be measured by RECIST 1.1.

  Estimate up to 2 years.

Secondary Outcomes (4)

• Overall Survival (OS)

  Estimate up to 5 years.

• Progression-free Survival (PFS)

  Estimate up to 2 years.

• Disease Control Rate (DCR)

  Estimate up to 2 years.

• Adverse events

  Estimate up to 2 years.

Study Arms (1)

Apatinib with chemotherapy

EXPERIMENTAL

Apatinib with oxaliplatin and S-1 treatment

Drug: Apatinib; Drug: Oxaliplatin; Drug: S1

Interventions

Apatinib DRUG

500mg oral qd

Also known as: Apatinib Mesylate Tablets

Apatinib with chemotherapy

Oxaliplatin DRUG

130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle

Also known as: Oxaliplatin for Injection

Apatinib with chemotherapy

S1 DRUG

According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle

Also known as: Tegafur Gimeracil Oteracil Potassium Capsule

Apatinib with chemotherapy

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: 18 to 70 years old, no gender limitation;
• Histopathological diagnosis of locally advanced, recurrent or metastatic HAS (pathological histomorphology and immunohistochemical diagnosis of AFP, sal-like 4(SALL4), Hep, glypican-3(GPC3), etc.);
• Immunohistochemical(IHC) human epidermal growth factor receptor-2 (HER2) negative persons; HER2 positive is defined as IHC 3+ or IHC 2+ and fluorescence in situ hybridization(FISH)+, and FISH positive is defined as the ratio of HER2 gene copy number to chromosome 17 centromere(CEP17) signal number ≥2.0;
• According to the RECIST 1.1 standard, at least one measurable lesion (spiral CT scan ≥10mm);
• ECOG performance status(PS): 0-2 points;
• The expected survival time is ≥3 months;
• The main organs are functionally normal, without serious blood, heart, lung, liver, kidney dysfunction and immune deficiency disease. The blood test meets the following requirements; (1) Routine blood examination, which must be met (no blood transfusion within 14 days);
• HGB≥100g/L;
• WBC≥4.0×10\^9/L; absolute neutrophil count(ANC) ≥2.0×10\^9/L;
• PLT≥2.0×10\^9/L; (2) The biochemical inspection must meet the following standards:
• <!-- -->
• BIL≤1.5 times the upper limit of normal (ULN);
• Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)≤2.5×ULN; if there is liver metastasis, ALT and AST≤5×ULN;
• serum Cr≤1.5×ULN, endogenous creatinine clearance≥50ml/min (Cockcroft-Gault formula); (3) Occult blood in stool (-); (4) Urine routine is normal, or urine protein \<(++), or 24-hour urine protein \<1.0g;
• The coagulation function is normal, without active bleeding and thrombosis disease;

You may not qualify if:

• Various types of liver inflammatory diseases (especially hepatitis A, B, and C viral hepatitis active period) and other diseases that may produce AFP such as liver cirrhosis;
• Germ cell tumors;
• Have previously received any regimen of palliative chemotherapy for gastric cancer;
• Have previously received apatinib treatment;
• S-1 and/or oxaliplatin have been used in the past 6 months;
• Those who have hypertension and cannot be reduced to the normal range after treatment with antihypertensive drugs (shrinking Pressure\>140mmHg or diastolic pressure\>90mmHg);
• Suffering from coronary heart disease ≥2 grade, arrhythmia corrected QT interval(QTc) interval prolonged male\> 450ms, female;\>470ms) and cardiac insufficiency;
• There are many factors that affect the absorption of oral drugs (such as inability to swallow, nausea and vomiting, chronic abdominal Diarrhea and intestinal obstruction, etc.);
• Patients at risk of gastrointestinal bleeding or those with a history of gastrointestinal bleeding within 1 month;
• Abnormal blood coagulation function (INR\>1.5×ULN, activated partial thromboplastin time(APTT)\>1.5×ULN), those with bleeding tendency;
• Those with thrombotic diseases or receiving anticoagulant treatment;
• Those with peripheral sensitive neuropathy with dysfunction;
• Central nervous system metastasis;
• Pregnant or lactating women;
• Those who have participated in other clinical research in the past 30 days;

Sponsors & Collaborators

• Peking University: lead

Study Sites (1)

Beijing Cancer Hospital / Peking University Cancer Hospital

Beijing, Beijing Municipality, China

Location

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

apatinib; Oxaliplatin; Injections; S 1 (combination)

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Drug Administration Routes; Drug Therapy; Therapeutics

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dean of VIP2 Gastrointestinal Cancer Division of Medical Department, Beijing Cancer Hospital

Study Record Dates

• First Submitted: April 26, 2021
• First Posted: April 28, 2021
• Study Start: May 11, 2021
• Primary Completion: July 6, 2023
• Study Completion: July 6, 2023
• Last Updated: February 21, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)